Danica Pension Livsforsikringsaktieselskab Invests $3.65 Million in Stryker Corporation $SYK

Danica Pension Livsforsikringsaktieselskab acquired a new stake in shares of Stryker Corporation (NYSE:SYK) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 11,607 shares of the medical technology company’s stock, valued at approximately $3,654,000.

Several other hedge funds also recently bought and sold shares of the company. Danske Bank A S purchased a new stake in shares of Stryker during the 2nd quarter worth about $211,000. Diversify Advisory Services LLC acquired a new position in Stryker in the second quarter worth approximately $5,817,000. Gables Capital Management Inc. bought a new position in Stryker during the second quarter valued at approximately $25,000. Strategic Wealth Advisors LLC raised its position in Stryker by 50.4% during the second quarter. Strategic Wealth Advisors LLC now owns 197 shares of the medical technology company’s stock valued at $62,000 after acquiring an additional 66 shares in the last quarter. Finally, First National Bank of Omaha lifted its stake in Stryker by 61.4% in the second quarter. First National Bank of Omaha now owns 8,129 shares of the medical technology company’s stock valued at $2,639,000 after acquiring an additional 3,092 shares during the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Stock Performance

Shares of NYSE SYK opened at $331.96 on Wednesday. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The business’s 50 day moving average is $325.56 and its two-hundred day moving average is $333.05. The company has a market cap of $127.33 billion, a P/E ratio of 34.40, a P/E/G ratio of 2.16 and a beta of 0.76. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $396.86.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating the consensus estimate of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.Stryker’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period in the prior year, the business earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, equities analysts expect that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s dividend payout ratio is 36.48%.

Analysts Set New Price Targets

Several brokerages have recently commented on SYK. UBS Group started coverage on shares of Stryker in a research note on Tuesday, July 28th. They set a “buy” rating and a $400.00 price target on the stock. Wall Street Zen raised shares of Stryker from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $361.00 price objective on shares of Stryker in a report on Friday, May 1st. Wolfe Research lowered Stryker from an “outperform” rating to a “peer perform” rating in a report on Thursday, August 13th. Finally, Canaccord Genuity Group reduced their price target on Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a research report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $386.28.

Insiders Place Their Bets

In other news, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the transaction, the vice president owned 10,582 shares in the company, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the transaction, the director directly owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This represents a 13.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 315,370 shares of company stock worth $98,463,501 in the last ninety days. Insiders own 4.60% of the company’s stock.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.